'Policy Forces' Retarding Pharmacogenomic-Backed Off-Label Rx Use | GenomeWeb
NEW YORK (GenomeWeb News) — “Policy forces” inside the US government are preventing genomic technologies from helping physicians make off-label prescribing decisions, according to a prominent US Food and Drug Administration official.
 
“Medicine is becoming more personalized as tools like genomics make it possible to tailor treatments on an individual basis,” Scott Gottlieb, deputy commissioner for medical and scientific affairs, said in a speech at Windhover's FDA/CMS Summit in Washington, DC, earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.